And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is particularly modest. We plan to catch up on our reading and napping, hang with a short person or two, and perhaps putter around the castle. And what about you? Now that spring is here, this may be an opportunity to plan a needed break. You could make time for someone special. Adventurous Anglophiles can amuse themselves betting on the Brexit outcome. Or you could simply plan the rest of your life. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon. …

Nearly 8,000 packets of a Vertex (VRTX) Pharmaceuticals (VRTX) cystic fibrosis drug were destroyed last year while the company and the National Health Service in England haggled over price, The Independent reports. Documents released by the House of Commons Health Committee show that 7,880 packets, each offering a 28-day supply of the drug and intended for distribution around Europe, exceeded their expiry date in 2018. This would be enough to provide the drug for around three months to every one of the 2,834 eligible patients in England.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • It would seem Commissioner G has interests that will, again, possibly continue long past his imminent departure. (Until, of course, they get tweeted down … not that he has seen much of that.) May I observe that we shall miss him, whether for good or ill? “Leich l’shalom,” Scott Gottlieb, MD….

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy